Open Access

Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma

  • Authors:
    • Jun Xin
    • Rong Xu
    • Shaokun Lin
    • Minghua Xin
    • Wenjie Cai
    • Jin Zhou
    • Changde Fu
    • Guangfu Zhen
    • Jinjin Lai
    • Yue Li
    • Pengfeng Zhang
  • View Affiliations

  • Published online on: June 17, 2016     https://doi.org/10.3892/ol.2016.4748
  • Pages: 1265-1270
  • Copyright: © Xin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the clinical potential of transcription factor (TCF) 21 methylation in the diagnosis of renal cell carcinoma (RCC). TCF21 methylation levels were quantified in renal tissues (55 cases of RCC tissue and 22 cases of normal tissue) and urine samples (33 cases of urine samples with RCC and 15 cases of normal urine samples) using pyrosequencing. Spearman's rank correlation coefficient was used to investigate the correlation between TCF21 methylation levels and clinical parameters (gender, age, smoking history, Fuhrman grade and clinical stage). The receiver operating characteristic (ROC) curve was utilized to evaluate the accuracy of predictive diagnosis of RCC. TCF21 methylation levels were significantly increased in RCC samples compared with normal renal tissues and urine samples. The Spearman's correlation analysis revealed that the TCF21 methylation level was positively associated with age (P=0.002), smoking (P=0.017) and Fuhrman grade (P=0.045) in RCC tissues and was positively associated with tumor size (P<0.001), Fuhrman grade (P=0.017) and clinical stage (P=0.017) in urine samples. ROC curves revealed that the cut‑off value, sensitivity and specificity were 23.61, 89.00 and 61.90%, respectively in tissue samples, and 26.84, 79 and 100%, respectively in urine samples. Furthermore, there were significant differences in the area under the curve between the tissue and urine samples (P=0.004). The results of the present study indicate that TCF21 may be used as a biomarker for diagnosing RCC, and TCF21 methylation levels in urine samples may be a useful means of diagnosing RCC.
View Figures
View References

Related Articles

Journal Cover

August-2016
Volume 12 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xin J, Xu R, Lin S, Xin M, Cai W, Zhou J, Fu C, Zhen G, Lai J, Li Y, Li Y, et al: Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma. Oncol Lett 12: 1265-1270, 2016
APA
Xin, J., Xu, R., Lin, S., Xin, M., Cai, W., Zhou, J. ... Zhang, P. (2016). Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma. Oncology Letters, 12, 1265-1270. https://doi.org/10.3892/ol.2016.4748
MLA
Xin, J., Xu, R., Lin, S., Xin, M., Cai, W., Zhou, J., Fu, C., Zhen, G., Lai, J., Li, Y., Zhang, P."Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma". Oncology Letters 12.2 (2016): 1265-1270.
Chicago
Xin, J., Xu, R., Lin, S., Xin, M., Cai, W., Zhou, J., Fu, C., Zhen, G., Lai, J., Li, Y., Zhang, P."Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma". Oncology Letters 12, no. 2 (2016): 1265-1270. https://doi.org/10.3892/ol.2016.4748